© 2002 Canadian Medical Association or its licensors Reason for posting: Health profession-

als are being warned of potentially fa-tal myocarditis, cardiomyopathy and heart failure associated with the an-tipsychotic drug clozapine.1 Cloza-pine-associated myocarditis has been previously estimated to occur at rates ranging from 1 in 10 0002 to 1 in 5003 patients. The drug’s manufacturer has reported 213 international cases of myocarditis (including 50 deaths), 85 % of which developed in the first 2 months of therapy.1 Most of the pa-tients were prescribed the drug in rec-ommended doses. Forty percent were under 30 years of age (64 % under 49)